Trade-Ideas: Thoratec (THOR) Is Today's

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Thoratec ( THOR) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Thoratec as such a stock due to the following factors:

  • THOR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $31.2 million.
  • THOR has traded 155,855 shares today.
  • THOR is down 3.1% today.
  • THOR was up 6.1% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in THOR with the Ticky from Trade-Ideas. See the FREE profile for THOR NOW at Trade-Ideas

More details on THOR:

Thoratec Corporation develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients. THOR has a PE ratio of 22.3. Currently there are 6 analysts that rate Thoratec a buy, no analysts rate it a sell, and 6 rate it a hold.

The average volume for Thoratec has been 942,700 shares per day over the past 30 days. Thoratec has a market cap of $1.5 billion and is part of the health care sector and health services industry. The stock has a beta of 0.80 and a short float of 5.6% with 3.50 days to cover. Shares are down 24.2% year-to-date as of the close of trading on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Thor Industries Stock Drops Double Digits on Mixed Earnings

Oil, Yellen and World GDP Growth: How to Trade the Week Ahead

HeartWare Falters After Announcing Valtech Cardio Acquisition

Thoratec (THOR) Moving On Heavy Volume In The Pre-Market Hours

Thoratec Sale May Be Precursor of More Cardiac Industry M&A